Genomic sequencing technologies promise an unbiased, comprehensive view of biological systems. Whether profiling a patient's microbiome, tracking an epidemic, or mapping viral drivers of cancer, researchers rely on these tools to capture every relevant genetic signal.
However, the underlying biochemistry of sample preparation creates systematic blind spots. The choice between sequencing DNA or RNA, the reliance on active cellular transcription, and the physical constraints of amplification protocols introduce severe selection biases. When a pathogen or genetic variant falls into one of these blind spots, it becomes entirely invisible to the assay. Understanding why these biases occur is essential for accurately interpreting metagenomic and clinical sequencing data.
The DNA-RNA Divide in Metagenomics
The most fundamental bias arises from the physical separation of nucleic acid classes during library preparation. Many standard metagenomic next-generation sequencing (mNGS) workflows isolate and sequence only DNA. While this simplifies processing and successfully captures bacteria, fungi, and DNA viruses, it creates a total "pathogen coverage gap" for RNA viruses.
In clinical diagnostics, this class restriction can lead to incomplete or dangerously misleading profiles. For example, Mingqiang Wang et al. demonstrated that DNA-based mNGS routinely fails to detect clinically relevant RNA viruses in patients suffering from severe community-acquired pneumonia (Identifying subgroup of severe community-acquired pneumonia based on clinical metagenomics, a multicenter retrospective cohort study). This diagnostic gap is further highlighted in a study on microbial lung-to-blood translocation (Microbial lung-to-blood translocation associates with systemic inflammation in severe pneumonia: evidence from paired plasma and lower respiratory tract metagenomics), where the authors noted that DNA-optimized metagenomic platforms cannot capture RNA virus dynamics, obscuring how these non-DNA pathogens contribute to systemic inflammatory responses.
Even advanced sample-enrichment protocols suffer from this limitation. The microfluidics-based enrichment and amplification protocol developed by Xing Shi et al. achieves strain-level resolution for airway metagenomics, yet because it is fundamentally designed for DNA, it completely misses RNA viruses and functional gene expression unless explicitly adapted for metatranscriptomics (Microfluidics-Based Enrichment and Whole-Genome Amplification Enable Strain-Level Resolution for Airway Metagenomics).
This bias is equally pervasive outside of acute respiratory infections:
- Host-Immune Interactions: In post-transplant monitoring, Asha Rani et al. found that standard DNA-targeted shotgun sequencing overlooks the RNA virome in kidney transplant recipients, preventing a complete understanding of viral-host immune dynamics (A diverse virome in kidney transplant patients contains multiple viral subtypes with distinct polymorphisms).
- Wildlife Surveillance: When surveying potential zoonotic risks in non-human primates, Ping Liu et al. observed that relying strictly on DNA metagenomics leaves a massive portion of the pathogenic viral community uncharacterized (Seasonal Metagenomic Survey of Pathogenic Microorganisms in Non-Human Primates in Mayanghe National Nature Reserve, China).
- Targeted Assays: Even targeted molecular tools exhibit this restriction; Yuan Chen et al. showed that multiplex real-time PCR assays designed only for DNA targets fail to capture co-infections involving RNA-based pathogens in complex clinical syndromes (Establishment and application of multiplex real-time PCR for simultaneous detection of four viruses associated with porcine reproductive failure).
The Transcriptional Silencing Gap
To capture RNA viruses or observe functional cellular activity, researchers frequently turn to transcriptomics (RNA sequencing). However, shifting the focus to RNA introduces the opposite bias: a transcriptional silencing gap.
Because RNA-seq only captures molecules that are actively being transcribed by the cell, any genetic element residing in a non-coding, latent, or transcriptionally silenced region of the genome remains entirely invisible.
DNA Level: [Active Gene] ---- [Silenced/Latent Viral DNA] ---- [Non-Coding Region]
| | |
Transcription: v v v
RNA Level: [mRNA Detected] [No Transcript] [No Transcript]
*TRANSCRIPTIONAL BLIND SPOT* *TRANSCRIPTIONAL BLIND SPOT*
This expression-dependent detection bias severely distorts the mapping of viral integration sites in host genomes. For instance, Irene Kraus Christiansen et al. demonstrated that identifying Human Papillomavirus (HPV) integration sites by looking for viral-host fusion transcripts fails to capture latent or silent integration events that do not produce RNA (Transcriptionally Active Regions Are the Preferred Targets for Chromosomal HPV Integration in Cervical Carcinogenesis).
Similarly, Seungyeul Yoo found that using RNA-seq to map Hepatitis B Virus (HBV) integration in liver cancer creates a systematic bias toward functional transcripts, completely missing the broader landscape of silent genomic alterations present at the DNA level (A pilot systematic genomic comparison of recurrence risks of hepatitis B virus-associated hepatocellular carcinoma with low- and high-degree liver fibrosis).
Computational tools designed to extract viral insights from transcriptomic data are bound by this same physical reality. The Venus pipeline, developed by Che-Yu Lee et al., offers high-resolution virus detection and fusion-site discovery from bulk and single-cell RNA-seq data, yet the authors emphasize that viral insertions into non-coding or transcriptionally silent regions remain fundamentally undetectable without paired DNA sequencing (Venus: An efficient virus infection detection and fusion site discovery method using single-cell and bulk RNA-seq data).
This bias is not unique to viruses; it also restricts host variant detection. The RESA framework, introduced by Tianyun Zhang et al., identifies cancer somatic mutations directly from single-cell RNA-seq data, but because it is limited to actively expressed genes, mutations in silent genomic regions remain a permanent blind spot (De novo identification of expressed cancer somatic mutations from single-cell RNA sequencing data).
Assay-Level Selection Biases and Attrition
Beyond the broad DNA vs. RNA dichotomy, narrower technical choices within extraction, amplification, and quality control protocols introduce finer-grained selection biases.
Extraction Specificity
Even when an assay is designed to capture both DNA and RNA, standard extraction kits are often optimized for double-stranded DNA or messenger RNA. Holger Sültmann et al. revealed that standard extraction protocols used in large-scale cancer genomic studies frequently fail to capture specific viral architectures, particularly single-stranded DNA or RNA viruses, skewing our understanding of viral associations across human cancers (The landscape of viral associations in human cancers).
Amplification and Sequence Divergence
Assays that rely on targeted amplification can suffer from systematic sample attrition when a pathogen mutates. Song Yang et al. observed that technical difficulties in amplifying highly divergent or mutated strains of Hepatitis C Virus (HCV) can cause those samples to fail quality control, leading to an underrepresentation of highly mutated strains in epidemiological datasets (Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6).
Titer Thresholds
To ensure high-quality sequencing reads, genomic surveillance pipelines often enforce strict viral load thresholds. As noted by Hayden Brochu et al., protocols requiring high viral titers systematically exclude samples with low viral loads, creating a selection bias that can miss early-stage infections or fail to capture viral evolution across different patient demographics (A program for real-time surveillance of SARS-CoV-2 genetics).
Structural Blind Spots
The physical design of an amplification strategy can also blind it to specific genomic structures. For example, Jenna M. Hasson et al. demonstrated that near-full-length HIV single-genome sequencing amplification approaches are structurally incapable of detecting solo long terminal repeats (LTRs). Because these solo LTRs comprise a significant portion of the latent proviral reservoir, the assay provides an incomplete map of the viral landscape (Differential HIV-1 Proviral Defects in Children vs. Adults on Antiretroviral Therapy).
Overcoming Sequencing Blind Spots
Biases in sequencing are not failures of technology, but rather consequences of biochemistry. A DNA extraction kit cannot capture an RNA molecule; an RNA transcript cannot reveal a silenced gene.
To build a truly complete map of host-pathogen interactions, viral integration, and microbial ecology, researchers must move away from single-omic paradigms. Overcoming these blind spots requires the deliberate integration of parallel DNA and RNA sequencing workflows, ensuring that what is silent at one molecular level can be captured at another.
Key Foundational Work
A diverse virome in kidney transplant patients contains multiple viral subtypes with distinct polymorphisms (2016) — contributed 1 concept elements to this direction.
Transcriptionally Active Regions Are the Preferred Targets for Chromosomal HPV Integration in Cervical Carcinogenesis (2015) — contributed 1 concept elements to this direction.
Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6 (2015) — contributed 1 concept elements to this direction.